美国实体器官移植受者非角质形成细胞皮肤癌风险谱
这项基于美国移植登记库与32个癌症登记库的队列研究纳入1987至2017年444 497例实体器官移植受者,识别2380例非角质形成细胞皮肤癌。黑色素瘤最常见(1471例),病毒相关肿瘤风险升高最明显,男性、移植时年龄较大、紫外线暴露相关因素和移植后时间延长与多种皮肤癌风险独立相关。
要点
- 移植受者中黑色素瘤最常见,占非角质形成细胞皮肤癌的61.8%。
- 卡波西肉瘤、梅克尔细胞癌和结外NK/T细胞淋巴瘤风险显著升高。
- 哺乳动物雷帕霉素靶蛋白抑制剂治疗与黑色素瘤发生率降低相关。
核心结论
- 病毒、紫外线暴露和免疫抑制与实体器官移植受者皮肤癌发生相关。
- 某些高危亚组可能受益于加强皮肤监测。
- 哺乳动物雷帕霉素靶蛋白抑制剂治疗可能对移植人群的黑色素瘤化学预防有效。
研究设计与样本
- 基于人群的队列研究,纳入1987年1月1日至2017年12月31日在美国接受移植的444 497例实体器官移植受者,链接国家移植登记库与32个癌症登记库数据。
- 数据分析时间为2021年4月1日至2021年9月30日。
- 使用标准化发病比评估相对于一般人群的风险,使用泊松回归评估危险因素。
主要发现
- 共识别2380例非角质形成细胞皮肤癌,移植时中位年龄50岁(范围0-96岁),274 276例(61.7%)为男性,272 241例(61.2%)为非西班牙裔白人。
- 黑色素瘤最常见(1471例,61.8%),其次为梅克尔细胞癌(334例,14.0%)、卡波西肉瘤(186例,7.8%)、皮脂腺癌(170例,7.1%)和皮肤淋巴瘤(108例,4.5%)。
- 病毒相关肿瘤风险升高最明显:卡波西肉瘤SIR 20.5(95%CI 17.7-23.7),梅克尔细胞癌SIR 16.2(95%CI 14.5-18.1),结外NK/T细胞淋巴瘤SIR 44.3(95%CI 5.37-160)。
- 皮脂腺癌SIR 15.2(95%CI 13.0-17.7),间变性大细胞淋巴瘤SIR 6.82(95%CI 4.53-9.85),弥漫性大B细胞淋巴瘤SIR 5.17(95%CI 3.28-7.76)。
- 男性、移植时年龄较大、紫外线暴露相关因素(非西班牙裔白人种族和族裔、居住在紫外线暴露较高地区、移植后诊断角质形成细胞癌)和移植后时间延长与多种皮肤癌风险独立相关;哺乳动物雷帕霉素靶蛋白抑制剂治疗与黑色素瘤发生率降低相关(发生率比0.75,95%CI 0.57-0.98)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Nonkeratinocyte skin cancers are an important cause of morbidity and mortality for immunosuppressed solid organ transplant recipients (SOTRs), but the spectrum of disease and risk factor characteristics are unknown. OBJECTIVE: To characterize the spectrum of disease and risk factors for common and rare nonkeratinocyte skin cancers in SOTRs. DESIGN, SETTING, AND PARTICIPANTS: This population-based cohort study included 444 497 SOTRs who underwent a transplant in the US between January 1, 1987, and December 31, 2017, using linked data from the national transplant registry and 32 cancer registries. Data analysis was conducted from April 1, 2021, to September 30, 2021. MAIN OUTCOMES AND MEASURES: Standardized incidence ratios (SIRs) were used to assess risk relative to the general population, and Poisson regression was used to evaluate risk factors. RESULTS: A total of 2380 nonkeratinocyte skin cancers were identified among 444 497 SOTRs (median age at transplant, 50 years; range, 0-96 years; 274 276 [61.7%] male; 272 241 [61.2%] non-Hispanic White). Melanoma was the most common cancer (1471 [61.8%]), followed by Merkel cell carcinoma (334 [14.0%]), Kaposi sarcoma (186 [7.8%]), sebaceous carcinoma (170 [7.1%]), and cutaneous lymphomas (108 [4.5%]). Risks were most strongly elevated for cancers associated with viruses, including Kaposi sarcoma (SIR, 20.5; 95% CI, 17.7-23.7), Merkel cell carcinoma (SIR, 16.2; 95% CI, 14.5-18.1), and extranodal natural killer/T-cell lymphoma (SIR, 44.3; 95% CI, 5.37-160). Risks were also significantly elevated for sebaceous carcinoma (SIR, 15.2; 95% CI, 13.0-17.7), anaplastic large cell lymphoma (SIR, 6.82; 95% CI, 4.53-9.85), and diffuse large B-cell lymphoma (SIR, 5.17; 95% CI, 3.28-7.76). Several characteristics were independently associated with greater risk for multiple skin cancer types, including male sex, older age at transplant, factors associated with UV radiation exposure (non-Hispanic White race and ethnicity, living in an area with higher UV radiation exposure, and posttransplant diagnosis of keratinocyte carcinoma), and increasing time since transplantation. Treatment with mammalian target of rapamycin inhibitors was associated with reduced melanoma incidence (incidence rate ratio, 0.75; 95% CI, 0.57-0.98). A total of 847 skin cancers (39.4%) occurred on the head and neck. CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that viruses, UV radiation exposure, and immunosuppression are associated with the development of skin cancer in SOTRs. Certain high-risk subgroups may benefit from increased skin surveillance, and treatment with mammalian target of rapamycin inhibitors could be effective for melanoma chemoprevention in the transplant population.
引用
- Sargen MR, Cahoon EK, Yu KJ, et al. Spectrum of Nonkeratinocyte Skin Cancer Risk Among Solid Organ Transplant Recipients in the US. JAMA Dermatol. 2022. PMID: 35262623. doi:10.1001/jamadermatol.2022.0036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。